Stephen Schuster, MD, presents Phase III trial findings at ASCO: Personalized Cancer Vaccine Boosts Progression-Free Survival in Patients with Lymphoma

June 1, 2009

Penn Medicine News Release

Stephen Schuster, MD
, an associate professor in the division of Hematology/Oncology, delivered a plenary presentation on Sunday during the annual meeting of the American Society of Clinical Oncology in Orlando describing the results of the Phase III trial of a personalized vaccine for follicular lymphoma patients who went into remission following chemotherapy. Patients who received a vaccine prepared from their own freshly isolated tumor cells combined with an immune-stimulating agent had a median time to relapse of 44.2 months, compared with 30.6 months for patients treated with the control vaccine... Read More

The findings, hailed as a major advance in personalized cancer therapy, were covered by NCI Bulletin, USA Today, Associated Press, Wall Street Journal, New York Times, ABC News (via Med Page Today), Bloomberg NewsHouston ChronicleAtlanta Journal Constitution and (via Health Day News), and other media outlets.